that the fusion proteins of NS5A and the fluorescent proteins remain intact within cells and serve as accurate markers of infection and as indicators of the subcellular localization of HCV-NS5A proteins.

Kinetics of HCV infection

Using those fluorescence-tagged HCV constructs, we analyzed more precisely the ratio and kinesics of HCV RNA-transfected cells and virus-infected cells by flow cytometry. After HCV RNA transfection, the percentages of JFH1-EYFP and JFH1-EYFP mutant-transfected cells were almost equivalent up to 2 days. Thereafter, JFH1-EYFP-positive cells began to decrease in number, while the mutant-transfected cells increased exponentially until 5 days post-transfection and then reached a plateau, when 52.2% of the cells were EYFP-positive (Fig. 5a). We collected the media from JFH1-EYFP and mutant-transfected cells at 2 days post-transfection, and added it onto uninfected Huh7.5.1 cells at a moi of 0.01. Similar to the results of the transfection assay, the population of JFH1-EYFP mutant-infected cells increased exponentially and reached a stable state at 6 days post-infection, when 39.2% of the cells were EYFP-positive (Fig. 5b). Calculating from the above data, the rate of expansion of HCV-infected cells was $2^{1.5}$/day. The cell-to-cell expansion of the JFH1-EYFP mutant infection was blocked by prior treatment of cells with anti-CD81 antibody (data not shown). This finding indicated that the expansion of the EGFP-positive cells was due to cell–cell spread of EYFP-tagged HCV and not the division of the virus-positive cells.

To further refine the calculation of the rate of cell-to-cell spread of infection, we carried out JFH1-EYFP mutant infection of uninfected Huh7.5.1 cells seeded at various densities from 2×10^3 to 2×10^5 cells/mL (Fig. 6). Flow cytometry showed that the rates of expansion of HCV-infected cells were $2^{1.5}$, $2^{2.3}$ and $2^{2.5}$/day at 2×10^3, 2×10^4 and 2×10^5 cells/cm², respectively. The ability of JFH1-EYFP to spread is greater in cells seeded at higher density. The maximum rate of expansion of HCV-infected cells was calculated as $2^{2.5}$/day.

Effects of antiviral drugs on HCV-infected cells

We next investigated the effects of antiviral agents on the infection kinetics of tagged-HCV. Eighteen hours after transfection of EYFP-tagged HCV RNA, the cells were treated with 10, 30 or 50 U/mL of IFN-α-2b or with 10 μM of protease inhibitor, BILN2061. JFH1-EYFP mutant-transfected cells were analyzed using flow


Figure 6   Rate of expansion of hepatitis C virus (HCV)-infected cells. The medium from JFH1-EYFP mutant was inoculated onto Huh7.5.1 cells seeded at different densities (2×10^3, 4×10^3, 1×10^4, 2×10^4 and 2×10^5 cells/cm²) with core antigen adjusted doses. The results of flow cytometric analysis are depicted as density plots. The ratios of EYFP-positive cells vs time are shown beneath. Assays were carried out in triplicate and the results are expressed as mean ± standard deviation. —■—, 2×10^3; ··◇··, 4×10^3; —▲—, 1×10^4; ··○··, 2×10^4; —●—, 2×10^5.

cytometry. As shown in Figure 7, treatment of cells with the two compounds suppressed the time-dependent increase of HCV propagation. In addition, IFN-α-2b suppressed the dose-dependent increase of HCV

Time after transfection (day)

|	1	2	3	4
Vehicle	2.51	18.21	37.98	49.96
PI	1.82	8.13	16.29	20.36
IFN 50U/ml	2.28	11.93	21.13	23.46
IFN 30U/ml	2.31	15.84	23.57	24.48
IFN 10U/ml	2.46	16.31	25.7	25.99

Figure 7 Effect of antiviral drugs on hepatitis C virus (HCV)-infected cells. Huh7.5.1 cells were transfected with JFH1-EYFP mutant RNA. Eighteen hours after transfection, cells were cultured with 10, 30 or 50 U/mL of interferon (IFN)-α-2b or 10 μM of the protease inhibitor BILN-2061. The cells were harvested at the days indicated and flow cytometry was performed. Ratios of EYFP-positive cells over time are shown at lower left. Plot values of 100% in each curve represent the EYFP expression levels in untreated cells (lower right). Assays were carried out in triplicate and the results are expressed as mean ± standard deviation. *$P < 0.05$. **$P < 0.01$. PI, protease inhibitor. · ◇ ·, vehicle; —●—, 50 U/mL; · ● ·, 30 U/mL; —○—, 10 U/mL; —■—, PI.

propagation. At all time points, the number of infected cells was significantly lower in the culture treated with the two compounds than in the untreated culture. The protease inhibitor suppressed infection faster than did IFN-α-2b. These data indicate that IFN and the protease inhibitor were not only able to suppress intracellular HCV replication levels but also to inhibit virus particle secretion and expansion of HCV-infected cell populations.

DISCUSSION

IN THIS STUDY, we used fluorescence-tagged HCV, in which virus assembly, particle secretion and re-infection functions are fully preserved (Fig. 1).[17] Utilizing the fluorescence-tagged HCV, we analyzed the rate of expansion of HCV infection using live-cell flow cytometric analyses (Figs 5–7). In the early periods of infection, the expansion of the virus-positive cell population increased exponentially and the maximum rate of expansion was calculated as $2^{2.5}$/day. It is not clear why HCV propagation reaches a plateau, but this observation, where HCV replication is limited in confluent cells, has been made previously.[26] Possible explanations include cell death due to over-confluence, depletion of the nucleoside triphosphate pools in resting cells, and/or cell cycle-dependent effects on virus RNA replication and translation.

Co-infection of the two virus clones, EYFP-JFH1 and AsRed mutant JFH1, showed that viruses with impaired particle secretion were able to replicate and expand virus-infected cells (Fig. 3). Although we have found no clear mechanism to explain those effects, we speculate that the secretion-defective virus (JFH1-EYFP) may assemble into infectious virus through *trans*-complementation of virus proteins via co-infection in a single cell or recombination of mutant and wild-type virus genomic RNA. The co-infection experiment showed that the increase of JFH1-AsRed mutant-positive cells was slower than in the single clone infection experiment (Fig. 2a). These findings suggest that viruses with impaired particle secretion (JFH1-EYFP) partially suppressed expansion of viruses with intact particle secretion (JFH1-AsRed mutant) through *trans*-suppression of cellular virus replication or competitive binding to cellular virus entry receptors.

After the development of HCV-JFH1 cell culture,[11] many variations of HCV cell culture systems have been developed. Lindenbach *et al.* developed a genotype 2a intragenotypic chimera, J6/JFH, in which the JFH1 structural region was replaced with that of J6, isolated

from a patient with chronic hepatitis.[27] The J6/JFH chimera is able to produce virus particles more efficiently than JFH1 but does not produce virus-induced cytopathic effects (CPE). Several marker protein-tagged viruses have been reported, in which viral infection could be visualized readily in living cells. A subgenomic replicon that expressed an NS5A-GFP fusion protein was reported first.[12] However, the clone lacked the structural regions that are required for virus propagation. Subsequently, full-length HCV reporter viruses were developed in which the EGFP gene was inserted into the NS5A-C-terminus of JFH1[13] or JC-1.[14] Jones *et al.* inserted the *renilla* luciferase gene into P7 of J6/JFH.[15] Unfortunately, the efficiency of virus production by the recombinant reporter viruses was greatly reduced compared to wild-type viruses. Very recently, it has been reported that a JFH1-based adaptive strain of a HCV reporter virus can produce infectious HCV particles as robustly as the JFH1 wild-type strain.[17] This virus system has overcome the serious limitations associated with the use and application of other reporter viruses.

Compared with the other HCV reporter viruses, the JFH1-EYFP/AsRed mutant is capable of producing amounts of HCV virus equivalent to that of the parental JFH1, which enables continuous passage of infection in cell culture and analyses using various research modalities, including flow cytometry and live-cell microcopy. Considering the current situation regarding the lack of singly effective, proven antiviral agents against HCV, other than IFN formulations, the search for potential antiviral agents will continue to be a dominant goal of research to improve clinical anti-HCV chemotherapeutics. This tagged HCV culture system may provide a very convenient tool for studies of the complete virus life cycle in live cells and of virus–host interactions, and it may be useful for high-throughput screening of drugs.

ACKNOWLEDGMENTS

REFERENCES

1 Sangiovanni A, Prati GM, Fasani P *et al*. The natural history of compensated cirrhosis due to hepatitis C virus: a 17-year cohort study of 214 patients. *Hepatology* 2006; 43: 1303–10.

2 Hiramatsu N, Oze T, Tsuda N *et al*. Should aged patients with chronic hepatitis C be treated with interferon and ribavirin combination therapy? *Hepatol Res* 2006; 35: 185–9.

3 Fukuhara T, Takeishi K, Toshima T *et al*. Impact of amino acid substitutions in the core region of HCV on multistep hepatocarcinogenesis. *Hepatol Res* 2009; 40: 171–8.

4 Tanaka Y, Nishida N, Sugiyama M, Tokunaga K, Mizokami M. lambda-Interferons and the single nucleotide polymorphisms: a milestone to tailor-made therapy for chronic hepatitis C. *Hepatol Res* 2010; 40: 449–60.

5 Fried MW, Shiffman ML, Reddy KR *et al*. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. *N Engl J Med* 2002; 347: 975–82.

6 Zeuzem S, Feinman SV, Rasenack J *et al*. Peginterferon alfa-2a in patients with chronic hepatitis C. *N Engl J Med* 2000; 343: 1666–72.

7 Sakamoto N, Watanabe M. New therapeutic approaches to hepatitis C virus. *J Gastroenterol* 2009; 44: 643–9.

8 Bartenschlager R, Lohmann V. Replication of hepatitis C virus. *J Gen Virol* 2000; 81: 1631–48.

9 Mottola G, Cardinali G, Ceccacci A *et al*. Hepatitis C virus nonstructural proteins are localized in a modified endoplasmic reticulum of cells expressing viral subgenomic replicons. *Virology* 2002; 293: 31–43.

10 Lohmann V, Koerner F, Koch J-O, Herian U, Theilmann L, Bartenschlager R. Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line. *Science* 1999; 285: 110–3.

11 Wakita T, Pietschmann T, Kato T *et al*. Production of infectious hepatitis C virus in tissue culture from a cloned viral genome. *Nat Med* 2005; 11: 791–6.

12 Moradpour D, Evans MJ, Gosert R *et al*. Insertion of green fluorescent protein into nonstructural protein 5A allows direct visualization of functional hepatitis C virus replication complexes. *J Virol* 2004; 78: 7400–9.

13 Kim SS, Peng LF, Lin W *et al*. A cell-based, high-throughput screen for small molecule regulators of hepatitis C virus replication. *Gastroenterology* 2007; 132: 311–20.

14 Schaller T, Appel N, Koutsoudakis G *et al*. Analysis of hepatitis C virus superinfection exclusion by using novel fluorochrome gene-tagged viral genomes. *J Virol* 2007; 81: 4591–603.

15 Jones DM, Gretton SN, McLauchlan J, Targett-Adams P. Mobility analysis of an NS5A-GFP fusion protein in cells actively replicating hepatitis C virus subgenomic RNA. *J Gen Virol* 2007; 88: 470–5.

16 Masaki T, Suzuki R, Murakami K *et al*. Interaction of hepatitis C virus nonstructural protein 5A with core protein is critical for the production of infectious virus particles. *J Virol* 2008; 82: 7964–76.

17 Han Q, Xu C, Wu C, Zhu W, Yang R, Chen X. Compensatory mutations in NS3 and NS5A proteins enhance the virus production capability of hepatitis C reporter virus. *Virus Res* 2009; 145: 63–73.

18 Lamarre D, Anderson PC, Bailey M *et al*. An NS3 protease inhibitor with antiviral effects in humans infected with hepatitis C virus. *Nature* 2003; 426: 186–9.

19 Lin TI, Lenz O, Fanning G *et al*. In vitro activity and preclinical profile of TMC435350, a potent hepatitis C virus protease inhibitor. *Antimicrob Agents Chemother* 2009; 53: 1377–85.

20 Zhong J, Gastaminza P, Cheng G *et al*. Robust hepatitis C virus infection in vitro. *Proc Natl Acad Sci USA* 2005; 102: 9294–9.

21 Sekine-Osajima Y, Sakamoto N, Mishima K *et al*. Development of plaque assays for hepatitis C virus-JFH1 strain and isolation of mutants with enhanced cytopathogenicity and replication capacity. *Virology* 2008; 371: 71–85.

22 Sekine-Osajima Y, Sakamoto N, Nakagawa M *et al*. Two flavonoids extracts from Glycyrrhizae radix inhibit in vitro hepatitis C virus replication. *Hepatol Res* 2009; 39: 60–9.

23 Jin H, Yamashita A, Maekawa S *et al*. Griseofulvin, an oral antifungal agent, suppresses hepatitis C virus replication in vitro. *Hepatol Res* 2008; 38: 909–18.

24 Itsui Y, Sakamoto N, Kakinuma S *et al*. Antiviral effects of the interferon-induced protein GBP-1 and its interaction with the hepatitis C virus NS5B protein. *J Gastroenterol* 2010; 45: 523–36.

25 Nishimura-Sakurai Y, Sakamoto N, Mogushi K *et al*. Comparison of HCV-associated gene expression and cell signaling pathways in cells with or without HCV replicon and in replicon-cured cells1. *J Gastroenterol* 2009 (EPub ahead of print).

26 Iro M, Witteveldt J, Angus AG *et al*. A reporter cell line for rapid and sensitive evaluation of hepatitis C virus infectivity and replication. *Antiviral Res* 2009; 83: 148–55.

27 Lindenbach BD, Meuleman P, Ploss A *et al*. Cell culture-grown hepatitis C virus is infectious in vivo and can be recultured in vitro. *Proc Natl Acad Sci USA* 2006; 103: 3805–9.

Sequences in the Interferon Sensitivity-Determining Region and Core Region of Hepatitis C Virus Impact Pretreatment Prediction of Response to PEG-Interferon Plus Ribavirin: Data Mining Analysis

Masayuki Kurosaki,[1] Naoya Sakamoto,[2] Manabu Iwasaki,[3] Minoru Sakamoto,[4] Yoshiyuki Suzuki,[5] Naoki Hiramatsu,[6] Fuminaka Sugauchi,[7] Akihiro Tamori,[8] Mina Nakagawa,[2] and Namiki Izumi, MD[1]*

[1]Division of Gastroenterology and Hepatology, Musashino Red Cross Hospital, Tokyo, Japan
[2]Department of Gastroenterology and Hepatology, Tokyo Medical and Dental University, Tokyo, Japan
[3]Department of Computer and Information Science, Seikei University, Tokyo, Japan
[4]First Department of Internal Medicine, University of Yamanashi, Yamanashi, Japan
[5]Department of Hepatology, Toranomon Hospital, Tokyo, Japan
[6]Department of Gastroenterology and Hepatology, Osaka University Graduate School of Medicine, Osaka, Japan
[7]Department of Gastroenterology and Metabolism, Nagoya City University Graduate School of Medical Sciences, Aichi, Japan
[8]Department of Hepatology, Osaka City University Medical School, Osaka, Japan

The aim of the present study was to clarify the significance of viral factors for pretreatment prediction of sustained virological response to pegylated-interferon (PEG-IFN) plus ribavirin (RBV) therapy for chronic hepatitis C using data mining analysis. Substitutions in the IFN sensitivity-determining region (ISDR) and at position 70 of the HCV core region (Core70) were determined in 505 patients with genotype 1b chronic hepatitis C treated with PEG-IFN plus RBV. Data mining analysis was used to build a predictive model of sustained virological response in patients selected randomly (n = 304). The reproducibility of the model was validated in the remaining 201 patients. Substitutions in ISDR (odds ratio = 9.92, $P < 0.0001$) and Core70 (odds ratio = 1.92, $P = 0.01$) predicted sustained virological response independent of other covariates. The decision-tree model revealed that the rate of sustained virological response was highest (83%) in patients with two or more substitutions in ISDR. The overall rate of sustained virological response was 44% in patients with a low number of substitutions in ISDR (0–1) but was 83% in selected subgroups of younger patients (<60 years), wild-type sequence at Core70, and higher level of low-density lipoprotein cholesterol (LDL-C) ($\geq$120 mg/dl). Reproducibility of the model was validated ($r^2 = 0.94$, $P < 0.001$). In conclusion, substitutions in ISDR and Core70 of HCV are significant predictors of response to PEG-IFN plus RBV therapy. A decision-tree model that includes these viral factors as predictors could identify patients with a high probability of sustained virological response. *J. Med. Virol. 83:445–452, 2011.*
© 2011 Wiley-Liss, Inc.

KEY WORDS: data mining; decision-tree model; ISDR; core region; PEG-interferon

INTRODUCTION

The combination of pegylated-interferon (PEG-IFN) plus ribavirin (RBV) is currently the most effective therapy for chronic hepatitis C, but the rate of sustained virological response after 48 weeks of therapy is about 50% in patients with HCV genotype 1b and a high HCV

RNA titer [Manns et al., 2001; Fried et al., 2002]. The most reliable means to predict sustained virological response is to monitor the viral response during the early weeks of treatment. The early virological response, defined as undetectable HCV RNA at week 12, is associated with a high rate of sustained virological response [Davis et al., 2003; Lee and Ferenci, 2008]. The rapid virological response, defined as undetectable HCV RNA at week 4 of therapy, is even more predictive of sustained virological response than the early virological response [Jensen et al., 2006; Yu et al., 2008; Izumi et al., 2010]. However, there is no established means that predicts the virological response before commencing treatment. Recent reports have revealed that single nucleotide polymorphisms located near the *IL28B* gene show a strong association with the response to PEG-IFN plus RBV therapy [Ge et al., 2009; Suppiah et al., 2009; Tanaka et al., 2009; Kurosaki et al., 2010c]. These findings indicate that the host factor is an important determinant of the treatment response. On the other hand, the present study's authors have reported that a stretch of 40 amino acids in the NS5A region of HCV, designated as the interferon sensitivity-determining region (ISDR), has a close association with the virological response to interferon mono-therapy [Enomoto et al., 1995, 1996; Kurosaki et al., 1997]. More recently, amino acid substitutions at positions 70 and 91 of the core region have been reported to be associated with response to PEG-IFN plus RBV combination therapy [Akuta et al., 2005, 2007a]. The impact of these HCV substitutions on treatment response is yet to be validated.

Decision-tree analysis is a core component of data mining analysis that can be used to build predictive models [Breiman et al., 1980]. This method has been used to define prognostic factors in various diseases such as prostate cancer [Garzotto et al., 2005], diabetes [Miyaki et al., 2002], melanoma [Averbook et al., 2002; Leiter et al., 2004], colorectal carcinoma [Zlobec et al., 2005; Valera et al., 2007], and liver failure [Baquerizo et al., 2003]. The major advantage of decision-tree analysis over logistic regression analysis is that the results of analysis are easy to understand. The simple allocation of patients into subgroups by following the flowchart form could define the predicted possibility of outcome [LeBlanc and Crowley, 1995].

Decision-tree analysis was used for the prediction of early virological response (undetectable HCV RNA within 12 weeks of therapy) to PEG-IFN and RBV combination therapy in chronic hepatitis C [Kurosaki et al., 2010a], and more recently for the pretreatment prediction of sustained virological response [Kurosaki et al., 2010b]. In the latter model, simple and noninvasive standard tests were used as parameters; specialized tests such as viral mutations and host genetics, or invasive tests such as liver histology, were not included because the aim of that model was for use in general medical practice, especially in some countries or areas where resources are limited. Thus, the impact of viral mutations or liver histology was not considered in that model.

The present study examined whether including viral substitutions in ISDR and the core region of HCV in the decision-tree model could improve its predictive accuracy over the previous model to identify chronic hepatitis C patients who are likely to respond to PEG-IFN plus RBV therapy.

MATERIALS AND METHODS

Patients

This multicenter retrospective cohort study included 505 chronic hepatitis C patients who were treated with PEG-IFN alpha-2b and RBV at Musashino Red Cross Hospital, Toranomon Hospital, Tokyo Medical and Dental University, Osaka University, Nagoya City University Graduate School of Medical Sciences, Yamanashi University, Osaka City University, and their related hospitals. The inclusion criteria were: (1) genotype 1b, (2) HCV RNA titer higher than 100 kIU/ml by quantitative PCR (Cobas Amplicor HCV Monitor v 2.0, Roche Diagnostic Systems, Pleasanton, CA), (3) no co-infection with hepatitis B virus or human immunodeficiency virus, (4) no other causes of liver disease, (5) patients having undergone liver biopsy prior to IFN treatment, (6) number of substitutions in ISDR having been determined, (7) substitutions in the amino acid positions 70 and 91 of the core region having been determined, and (8) completion of at least 12 weeks of therapy. Patients were treated with PEG-IFN alpha-2b (1.5 μg/kg) weekly plus RBV. The daily dose of RBV was adjusted by weight: 600 mg for <60 kg, 800 mg for 60–80 kg, and 1,000 mg for >80 kg. For the analysis, patients were assigned randomly to either the model building (304 patients) or validation (201 patients) groups. There were no significant differences in the clinical backgrounds between these two groups (Table I). Informed consent was obtained from each patient. The study protocol conformed to the ethical guidelines of the Declaration of Helsinki and was approved by the institutional review committees of all concerned hospitals.

Laboratory Tests

Hematological tests, blood chemistry, and HCV RNA titer were analyzed before therapy and at least once every month during therapy. Sequences of ISDR and the core region of HCV were determined by direct sequencing after amplification by reverse transcription and polymerase chain reaction as reported previously. At position 70 of the core region (Core70), arginine was defined as the wild type, and glutamine or histidine was defined as the mutant type. At position 91 of the core region, leucine was defined as the wild type and methionine was defined as the mutant type, as described previously [Akuta et al., 2005]. Fibrosis and activity were scored according to the METAVIR scoring system [Bedossa and Poynard, 1996]. Fibrosis was staged on a scale of 0–4: F0 (no fibrosis), F1 (mild fibrosis), F2 (moderate fibrosis), F3 (severe fibrosis), and F4 (cirrhosis). Activity of necroinflammation was graded on a scale of

TABLE I. Comparison of Pretreatment Factors Between Model Building and Validation Patients

	Model (n = 304)	Validation (n = 201)	P-value
Age (years)	55.6 (9.4)	56.0 (12.2)	0.80
Male (%)	53 (%)	55 (%)	0.13
Body mass index (kg/m^2)	23.1 (3.1)	23.1 (4.0)	0.99
Albumin (g/dl)	4.0 (0.3)	4.0 (0.3)	0.47
Creatinine (mg/dl)	0.72 (0.15)	0.72 (0.14)	0.62
AST (IU/L)	63.3 (45.6)	58.9 (46.4)	0.91
ALT (IU/L)	78.7 (58.6)	74.5 (67.5)	0.68
GGT (IU/L)	53.2 (49.1)	57.4 (63.5)	0.43
Total cholesterol (mg/dl)	170.9 (32.6)	169.4 (34.1)	0.33
Triglyceride (mg/dl)	107.0 (44.7)	105.7 (48.0)	0.90
LDL-C (mg/dl)	95.5 (28.0)	96.4 (28.8)	0.34
White blood cell count (/μl)	4,902 (1,489)	4,906 (1,319)	0.86
Hemoglobin (g/dl)	14.1 (1.3)	14.3 (1.4)	0.09
Platelets (10^9/L)	164 (56)	172 (55)	0.68
HCVRNA (10^3 IU/ml)	1,859 (1,468)	2,021 (1,393)	0.09
ISDR mutations: ≥2 (%)	15 (%)	20 (%)	0.11
Core70: mutant (%)	36 (%)	29 (%)	0.22
Core91: mutant (%)	40 (%)	36 (%)	0.20
Fibrosis: F2–4 (%)	49 (%)	48 (%)	0.36
Activity: A2–3 (%)	42 (%)	34 (%)	0.10

AST, aspartate aminotransferase; ALT, alanine aminotransferase; GGT, gamma-glutamyltransferase; LDL-C, low-density-lipoprotein-cholesterol; ISDR, interferon sensitivity-determining region. Data expressed as mean (SD).

0–3: A0 (no activity), A1 (mild activity), A2 (moderate activity), and A3 (severe activity). Sustained virological response was defined as undetectable HCV RNA by qualitative PCR with a lower detection limit of 50 IU/ml (Amplicor, Roche Diagnostic Systems) at week 24 after the completion of therapy.

Statistical Analysis

A database of pretreatment variables included hematological tests (hemoglobin level, white blood cell count, and platelet count), blood chemistry tests (serum levels of creatinine, albumin, aspartate aminotransferase, alanine aminotransferase (ALT), gamma-glutamyltransferase (GGT), total cholesterol, triglyceride, and low-density lipoprotein cholesterol (LDL-C)), viral factors (HCV RNA titer, number of substitutions in ISDR, substitutions in the amino acid positions 70 and 91 of the core region), histological findings (stage of fibrosis and grade of activity) and patient characteristics (age, sex, and body mass index). Based on this database, decision-tree analysis was used to define a predictive model for sustained virological response.

Student's t-test was used for the univariable comparison of quantitative variables and Fisher's exact test was used for the comparison of qualitative variables. For the multivariable analysis for factors associated with sustained virological response, logistic regression models with backward selection were used to identify independent predictors of sustained virological response. Variables that showed significant association with sustained virological response by univariable analysis were included in the multivariable analysis. IBM-SPSS software v.15.0 (SPSS, Inc., Chicago, IL) was used for these analyses. For the decision-tree analysis [Segal and

Bloch, 1989], the data mining software IBM SPSS Modeler 13 (IBM SPSS, Inc.) was used, as reported previously [Kurosaki et al., 2010a,b]. In brief, the software searched for the optimal split variables to build a decision-tree structure. The entire study population was first evaluated to determine the variables and cut-off points for the most significant division into two subgroups having different probabilities of sustained virological response. Thereafter, analysis was repeated on all subgroups in the same way until either no additional significant variable was detected or the sample size was below 20.

RESULTS

Generation of the Decision-Tree Model

The decision-tree analysis selected five predictive variables to produce six subgroups of patients (Fig. 1). The number of substitutions in ISDR was selected as the best predictor of sustained virological response. The possibility of achieving sustained virological response was 83% for patients with two or more substitutions in ISDR compared with 44% for patients with a single or no substitution. Among patients with a single or no substitution in ISDR, age, with an optimal cut-off of 60 years, was selected as the variable of second split. Patients younger than 60 had the higher probability of sustained virological response (55%) compared with those older than 60 years (31%). Among younger patients, amino acid substitution at Core70 was selected as the third variable of split—wild-type sequence being the predictor of favorable response compared with the mutant type (65% vs. 36%). Among patients with wild-type Core70, the level of serum LDL-C was selected as the fourth variable of split, with an optimal cutoff of

Fig. 1. Decision-tree model. Boxes indicate the factors used for splitting and the cutoff value for the split. Pie charts indicate the rate of sustained virological response for each group of patients after splitting. Terminal subgroups of patients discriminated by the analysis are numbered from 1 to 7. The rate of sustained virological response was >80% in subgroups 1 and 2, 64% in subgroup 3, and 31–36% in subgroups 4, 5, and 6. LDL-C represents low-density lipoprotein cholesterol and Core70 represents amino acid substitution at position 70 of the core region.

120 mg/dl. Patients with higher LDL-C level had the higher probability of sustained virological response (83% vs. 50%). The stage of fibrosis was selected as the final variable of split, with significant fibrosis (F2–4) being the predictor of lower sustained virological response probability (64% vs. 32%).

Among the six subgroups derived by this decision tree, the subgroup of patients with two or more substitutions in ISDR (subgroup 1) or with a single or no substitution in ISDR but younger than 60 years of age, having the wild-type Core70 and high serum level of LDL-C (≥120 mg/dl) (subgroup 2) showed the highest probability of sustained virological response (83%).

Validation of the Decision-Tree Model

The decision-tree model was validated using a validation dataset of 201 cases that were not included the model-building dataset. Each patient in the validation set was allocated to subgroups 1–6 using the flowchart form of the decision tree. The rates of sustained virological response were 75% for subgroup 1, 73% for subgroup 2, 65% for subgroup 3, 41% for subgroup 4, 46% for subgroup 5, and 33% for subgroup 6. The rates of sustained virological response for each subgroup of patients were correlated closely between the model building dataset and the validation dataset ($r^2 = 0.94$) (Fig. 2).

The six subgroups were reconstructed into three groups according to their rate of sustained virological response: the high-probability group consisted of subgroups 1 and 2, the intermediate-probability group consisted of subgroup 3, and the low-probability group consisted of subgroups 4, 5, and 6. The rate of sustained virological response in the high-probability group was high on a consistent basis: 83% for model-building patients and 74% for validation patients. The rate of sustained virological response in the intermediate-probability group was 64% for model building patients and 65% for internal validation patients. The rate of sustained virological response in the low-probability group was low on a consistent basis: 32% for model-building patients and 36% for internal validation patients (Fig. 3). Thirty percent of the patients were classified into the high-probability group and 10% of the patients were classified into intermediate-probability group, which means that about 40% of patients with higher than average probability of achieving sustained virological response were identified.

Effect of Dose Reductions of PEG-IFN and RBV

The possible effect of drug reductions was analyzed in the three groups of patients divided by decision tree (low-, intermediate-, and high-probability groups)

Fig. 2. Validation of the decision-tree analysis: Subgroup-stratified comparison of the rate of sustained virological response. Each patient in the validation set was allocated to subgroups 1–6 by following the flowchart form of the decision tree, and the rates of sustained virological response were then calculated and plotted for each subgroup. The x-axis represents the rate of sustained virological response in the model-building datasets and the y-axis represents the rate of sustained virological response in the validation datasets. The rates of achieving sustained virological response in each subgroup of patients correlated closely between the model-building dataset and the validation dataset (correlation coefficient: $r^2 = 0.94$).


Fig. 3. Comparison of sustained virological response rates between groups divided by the decision tree. The rate of sustained virological response was compared between three groups of patients as divided by the decision-tree analysis. Black, gray, and white boxes indicate the low-probability group (subgroup 4, 5, and 6), intermediate-probability group (subgroup 3), and high-probability group (subgroup 1 and 2), respectively. The rate of sustained virological response showed significant difference between the three groups.

(Fig. 4). Patients were stratified according to the cumulative drug exposure with PEG-IFN and RBV: the good adherence group consisted of patients who took ≥80% planned doses of both PEG-IFN and RBV; the poor adherence group consisted of patients who took <80% of planned doses of both PEG-IFN and RBV. Even after adjustment for drug adherence, the three groups of patients divided by decision-tree analysis still had low, intermediate, and high probability of achieving sustained virological response, respectively, indicating that this model predicts sustained virological response independent of drug exposure.

Multivariable Logistic Regression Analysis

Age, sex, serum levels of creatinine, ALT, GGT, LDL-C, hemoglobin, platelet count, HCV RNA titer, ISDR substitution, substitution at Core70, substitution at Core91, histological stage of fibrosis, and grade of activity were found to be associated with sustained virological response by standard univariable analysis. Multivariable analysis including these factors showed that age, sex, LDL-C levels, GGT levels, platelet count, ISDR substitution, and substitution at Core70 showed independent associations with sustained virological response (Table II). Substitution in ISDR had the highest odds ratio, at 9.92. Fibrosis, which was selected as a significant predictor of response in the decision-tree analysis, was not found to be an independent predictor of response in standard multivariable analysis, indicating that the decision-tree analysis could identify significant predictors that would apply specifically to selected patients.

DISCUSSION

The present study revealed that viral factors such as substitutions in ISDR and Core70 are significant and independent predictors of sustained virological response to PEG-IFN plus RBV in chronic hepatitis C. In a decision-tree model for the pretreatment prediction of sustained virological response, the number of substitutions in ISDR was the best predictor of sustained virological response, followed by younger age, wild-type sequence at Core70, higher level of LDL-C, and absent fibrosis. This decision-tree model could identify patients with high probability of sustained virological response (83%) among difficult-to-treat genotype 1b chronic hepatitis C patients. Using this model, rapid estimates of the response before treatment can be made by allocating patients to specific subgroups with a defined rate of response simply by following the flowchart form. Because more potent therapy, such as a combination of protease inhibitor, PEG-IFN, and RBV, is under clinical trial and may become available in the near future [Hezode et al., 2009; McHutchison et al., 2009], pretreatment prediction of the likelihood of sustained virological response may be useful for both patients and physicians to support clinical decisions whether to start current standard therapy or to wait for emerging new therapies.

Fig. 4. Comparison of the rate of sustained virological response between the decision-tree groups stratified by drug adherence. The three groups of patients divided by the decision tree (black, gray, and white boxes indicating the low-, intermediate-, and high-probability groups, respectively) were further stratified according to cumulative drug exposure to PEG-IFN and RBV.

Two or more substitutions in ISDR had a strong impact on sustained virological response, because this factor was selected as a top variable in decision-tree analysis and had the highest odds ratio in multivariable analysis. Moreover, even among patients with un-favorable ISDR (0 or 1 mutation), younger patients (<60 years) with the wild-type sequence at Core70 and high level of LDL-C (≥120 mg/dl) had a high rate of sustained virological response. The sustained virological response rate of these two subgroups of patients was 83% in the model-building patients and 75% in the validation patients. Thus, patients with high possibility of sustained virological response could be extracted by the combined analysis of ISDR and Core70. These patients may be the best-suited candidates for treatment with the current combination therapy. Conversely, the following patients with 0–1 mutation in ISDR had a low probability of sustained virological response (32–35%): (1) older (>60 years); or (2) younger (<60 years) patients but having mutant-type sequence at Core70; or (3) younger (<60 years) patients having a wild-type sequence at Core70, but having a low level of LDL-C (<120 mg/dl) and advanced fibrosis. These patients may

be advised to wait for a more effective therapy. Decision may be made on a case-by-case basis, taking into account the potential risk of disease progression while waiting.

In a previous decision-tree model using simple and noninvasive standard tests that are available readily worldwide [Kurosaki et al., 2010b], the rate of sustained virological response was at most 65–76% among those in the high-probability group. That model focused on use by general physicians in routine general practice, especially where specialized resources, such as liver biopsy or determination of viral sequences, are not available. In that model, younger age, male sex, higher platelet counts, lower alpha-fetoprotein (AFP) levels, and lower GGT levels were identified as favorable predictive parameters. Higher AFP levels and lower platelet counts that are hallmarks of advanced fibrosis [Shiratori and Omata, 2000; Akuta et al., 2007b] were associated with low probability of sustained virological response in that model. On the other hand, the present analysis aimed to clarify the significance of viral factors for pretreatment prediction of sustained virological response, and to build an advanced model that may be used by specialist physicians engaged in the

TABLE II. Multivariable Logistic Regression Analysis for Factors Associated With SVR

Parameter		Odds	95% CI	P-value
Age (years)	<60 vs. ≥60	2.28	1.31–3.94	0.003
Sex	Male vs. female	3.36	1.87–5.99	<0.0001
GGT (IU/L)	<40 vs. ≥40	2.65	1.45–4.85	0.002
LDL-C (mg/dl)	≥120 vs. <120	1.79	0.91–3.53	0.094
Platelets (109/L)	≥120 vs. <120	2.69	1.22–5.90	0.014
ISDR mutations	≥2 vs. 0–1	9.92	3.71–26.54	<0.0001
Core70	Wild vs. mutant	1.92	1.07–3.47	0.030

GGT, gamma-glutamyltransferase; LDL-C, low-density-lipoprotein-cholesterol; ISDR, interferon sensitivity-determining region.

treatment of hepatitis. In the present model, stage of fibrosis was selected as a predictive factor, but at lower level of significance than HCV mutations. The predicted rate of sustained virological response in the high-probability group of the present model is higher than that in the previous model (75–83% vs. 65–76%). These results indicate that substitutions in ISDR and Core70 were important pretreatment predictors of sustained virological response. Determination of these viral factors is not available readily in clinical practice, but is of value for improving the accuracy of pretreatment prediction of sustained virological response.

Substitutions in ISDR and Core70 have been reported previously to be associated with efficacy of IFN therapy. The association between the number of substitutions in ISDR and response to therapy was demonstrated originally in patients treated with IFN mono-therapy [Enomoto et al., 1995, 1996; Kurosaki et al., 1997], but recent studies have reported a positive correlation with PEG-IFN and RBV combination therapy as well [Munoz de Rueda et al., 2008; Shirakawa et al., 2008; Ikeda et al., 2009]. Another important viral factor relevant to treatment response is amino acid substitution in Core70. The sequence of this amino acid was reported originally to be associated with nonresponse to therapy [Akuta et al., 2005], but subsequent studies confirmed the positive correlation of a wild-type Core70 with sustained virological response [Akuta et al., 2009]. The multiple logistic regression analysis showed that ISDR and Core70 were independent factors associated with sustained virological response along with host factors. How these important viral factors and other host factors can be combined to predict response to PEG-IFN plus RBV is an important clinical question. Decision-tree modeling can make the response probability apparent by combining all these factors. Some factors that may be associated with treatment outcome, such as levels of ferritin or homocysteine, were not included. This may be a potential limitation of the present study.

It is of interest that a recent study by Li et al. [2010] has shown that a high serum level of LDL-C is linked to the *IL28B* major allele (CC in rs12979860). In that study, a high serum level of LDL-C was associated with sustained virological response, but it was no longer significant when analyzed together with the *IL28B* genotype in multivariate analysis. Thus, the association between treatment response and LDL cholesterol levels in the present study may reflect the underlining link of LDL cholesterol levels to the *IL28B* genotype. Recent reports indicate that the *IL28B* genotype and HCV substitutions are correlated closely [Akuta et al., 2010; Kurosaki et al., 2010c]. Still, Core70 [Akuta et al., 2010] or ISDR [Kurosaki et al., 2010c] were predictors of response to therapy independent of *IL28B* genotype. Future study is needed to elucidate the possible mechanisms underlying the association between HCV sequences and host genetic factors, and also the role of host and viral factors for the prediction of treatment response.

In conclusion, a data mining analysis emphasized the impact of substitutions in ISDR and Core70 on pretreatment prediction of sustained virological response to PEG-IFN plus RBV therapy. A decision-tree model that includes substitutions in ISDR and Core70 of HCV could identify patients with high probability of sustained virological response, and could thereby improve the predictive accuracy over predictions that are based on standard tests.

REFERENCES

Akuta N, Suzuki F, Sezaki H, Suzuki Y, Hosaka T, Someya T, Kobayashi M, Saitoh S, Watahiki S, Sato J, Matsuda M, Arase Y, Ikeda K, Kumada H. 2005. Association of amino acid substitution pattern in core protein of hepatitis C virus genotype 1b high viral load and non-virological response to interferon-ribavirin combination therapy. Intervirology 48:372–380.

Akuta N, Suzuki F, Kawamura Y, Yatsuji H, Sezaki H, Suzuki Y, Hosaka T, Kobayashi M, Arase Y, Ikeda K, Kumada H. 2007a. Predictive factors of early and sustained responses to peginterferon plus ribavirin combination therapy in Japanese patients infected with hepatitis C virus genotype 1b: Amino acid substitutions in the core region and low-density lipoprotein cholesterol levels. J Hepatol 46:403–410.

Akuta N, Suzuki F, Kawamura Y, Yatsuji H, Sezaki H, Suzuki Y, Hosaka T, Kobayashi M, Arase Y, Ikeda K, Kumada H. 2007b. Predictors of viral kinetics to peginterferon plus ribavirin combination therapy in Japanese patients infected with hepatitis C virus genotype 1b. J Med Virol 79:1686–1695.

Akuta N, Suzuki F, Hirakawa M, Kawamura Y, Yatsuji H, Sezaki H, Suzuki Y, Hosaka T, Kobayashi M, Saitoh S, Arase Y, Ikeda K, Kumada H. 2009. A matched case-controlled study of 48 and 72 weeks of peginterferon plus ribavirin combination therapy in patients infected with HCV genotype 1b in Japan: Amino acid substitutions in HCV core region as predictor of sustained virological response. J Med Virol 81:452–458.

Akuta N, Suzuki F, Hirakawa M, Kawamura Y, Yatsuji H, Sezaki H, Suzuki Y, Hosaka T, Kobayashi M, Saitoh S, Arase Y, Ikeda K, Chayama K, Nakamura Y, Kumada H. 2010. Amino acid substitution in hepatitis C virus core region and genetic variation near the interleukin 28B gene predict viral response to telaprevir with peginterferon and ribavirin. Hepatology 52:421–429.

Averbook BJ, Fu P, Rao JS, Mansour EG. 2002. A long-term analysis of 1018 patients with melanoma by classic Cox regression and tree-structured survival analysis at a major referral center: Implications on the future of cancer staging. Surgery 132:589–602.

Baquerizo A, Anselmo D, Shackleton C, Chen TW, Cao C, Weaver M, Gornbein J, Geevarghese S, Nissen N, Farmer D, Demetriou A, Busuttil RW. 2003. Phosphorus ans an early predictive factor in patients with acute liver failure. Transplantation 75:2007–2014.

Bedossa P, Poynard T. 1996. An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group. Hepatology 24:289–293.

Breiman LJH, Friedman RA, Olshen CJ, Stone CM. 1980. Classification and regression trees. CA: Wadsworth.

Davis GL, Wong JB, McHutchison JG, Manns MP, Harvey J, Albrecht J. 2003. Early virologic response to treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C. Hepatology 38:645–652.

Enomoto N, Sakuma I, Asahina Y, Kurosaki M, Murakami T, Yamamoto C, Izumi N, Marumo F, Sato C. 1995. Comparison of full-length sequences of interferon-sensitive and resistant hepatitis C virus 1b. Sensitivity to interferon is conferred by amino acid substitutions in the NS5A region. J Clin Invest 96:224–230.

Enomoto N, Sakuma I, Asahina Y, Kurosaki M, Murakami T, Yamamoto C, Ogura Y, Izumi N, Marumo F, Sato C. 1996. Mutations in the nonstructural protein 5A gene and response to interferon in patients with chronic hepatitis C virus 1b infection. N Engl J Med 334:77–81.

Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Goncales FL, , Haussinger D, Diago M, Carosi G, Dhumeaux D, Craxi A, Lin A, Hoffman J, Yu J. 2002. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 347:975–982.

Garzotto M, Beer TM, Hudson RG, Peters L, Hsieh YC, Barrera E, Klein T, Mori M. 2005. Improved detection of prostate cancer using classification and regression tree analysis. J Clin Oncol 23:4322–4329.

Ge D, Fellay J, Thompson AJ, Simon JS, Shianna KV, Urban TJ, Heinzen EL, Qiu P, Bertelsen AH, Muir AJ, Sulkowski M, McHutchison JG, Goldstein DB. 2009. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 461:399–401.

Hezode C, Forestier N, Dusheiko G, Ferenci P, Pol S, Goeser T, Bronowicki JP, Bourliere M, Gharakhanian S, Bengtsson L, McNair L, George S, Kieffer T, Kwong A, Kauffman RS, Alam J, Pawlotsky JM, Zeuzem S. 2009. Telaprevir and peginterferon with or without ribavirin for chronic HCV infection. N Engl J Med 360: 1839–1850.

Ikeda H, Suzuki M, Okuse C, Yamada N, Okamoto M, Kobayashi M, Nagase Y, Takahashi H, Matsunaga K, Matsumoto N, Itoh F, Yotsuyanagi H, Koitabashi Y, Yasuda K, Iino S. 2009. Short-term prolongation of pegylated interferon and ribavirin therapy for genotype 1b chronic hepatitis C patients with early viral response. Hepatol Res 39:753–759.

Izumi N, Nishiguchi S, Hino K, Suzuki F, Kumada Y, Itoh Y, Asahina Y, Tamori A, Hiramatsu N, Hayashi N, Kudo M. 2010. Management of hepatitis C; Report of the consensus meeting at the 45th annual meeting of the Japan society of hepatology (2009). Hepatol Res 40:347–368.

Jensen DM, Morgan TR, Marcellin P, Pockros PJ, Reddy KR, Hadziyannis SJ, Ferenci P, Ackrill AM, Willems B. 2006. Early identification of HCV genotype 1 patients responding to 24 weeks peginterferon alpha-2a (40 kd)/ribavirin therapy. Hepatology 43:954–960.

Kurosaki M, Enomoto N, Murakami T, Sakuma I, Asahina Y, Yamamoto C, Ikeda T, Tozuka S, Izumi N, Marumo F, Sato C, Ogura Y. 1997. Analysis of genotypes and amino acid residues 2209 to 2248 of the NS5A region of hepatitis C virus in relation to the response to interferon-beta therapy. Hepatology 25:750–753.

Kurosaki M, Matsunaga K, Hirayama I, Tanaka T, Sato M, Yasui Y, Tamaki N, Hosokawa T, Ueda K, Tsuchiya K, Nakanishi H, Ikeda H, Itakura J, Takahashi Y, Asahina Y, Higak M, Enomoto N, Izumi N. 2010a. A predictive model of response to peginterferon ribavirin in chronic hepatitis C using classification and regression tree analysis. Hepatol Res 40:251–260.

Kurosaki M, Sakamoto N, Iwasaki M, Sakamoto M, Suzuki Y, Hiramatsu N, Suguchi F, Yatsuhashi H, Izumi N. 2010b. Pretreatment prediction of response to peginterferon plus ribavirin therapy in genotype 1 chronic hepatitis C using data mining analysis. J Gastroenterol DOI: 10.1007/s00535-010-0322-5.

Kurosaki M, Tanaka Y, Nishida N, Sakamoto N, Enomoto N, Honda M, Sugiyama M, Matsuura K, Sugauchi F, Asahina Y, Nakagawa M, Watanabe M, Sakamoto M, Maekawa S, Sakai A, Kaneko S, Ito M, Masaki N, Tokunaga K, Izumi N, Mizokami M. 2010c. Pretreatment prediction of response to pegylated-interferon plus ribavirin for chronic hepatitis C using genetic polymorphism in IL28B and viral factors. J Hepatol DOI: 10.1016/j.jhep.2010.07.037.

LeBlanc M, Crowley J. 1995. A review of tree-based prognostic models. Cancer Treat Res 75:113–124.

Lee SS, Ferenci P. 2008. Optimizing outcomes in patients with hepatitis C virus genotype 1 or 4. Antivir Ther 13:9–16.

Leiter U, Buettner PG, Eigentler TK, Garbe C. 2004. Prognostic factors of thin cutaneous melanoma: An analysis of the central malignant melanoma registry of the German Dermatological Society. J Clin Oncol 22:3660–3667.

Li JH, Lao XQ, Tillmann HL, Rowell J, Patel K, Thompson A, Suchindran S, Muir AJ, Guyton JR, Gardner SD, McHutchison JG, McCarthy JJ. 2010. Interferon-lambda genotype and low serum low-density lipoprotein cholesterol levels in patients with chronic hepatitis C infection. Hepatology 51:1904–1911.

Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, Goodman ZD, Koury K, Ling M, Albrecht JK. 2001. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: A randomised trial. Lancet 358:958–965.

McHutchison JG, Everson GT, Gordon SC, Jacobson IM, Sulkowski M, Kauffman R, McNair L, Alam J, Muir AJ. 2009. Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection. N Engl J Med 360:1827–1838.

Miyaki K, Takei I, Watanabe K, Nakashima H, Omae K. 2002. Novel statistical classification model of type 2 diabetes mellitus patients for tailor-made prevention using data mining algorithm. J Epidemiol 12:243–248.

Munoz de Rueda P, Casado J, Paton R, Quintero D, Palacios A, Gila A, Quiles R, Leon J, Ruiz-Extremera A, Salmeron J. 2008. Mutations in E2-PePHD, NS5A-PKRBD, NS5A-ISDR, and NS5A-V3 of hepatitis C virus genotype 1 and their relationships to pegylated interferon-ribavirin treatment responses. J Virol 82:6644–6653.

Segal MR, Bloch DA. 1989. A comparison of estimated proportional hazards models and regression trees. Stat Med 8:539–550.

Shirakawa H, Matsumoto A, Joshita S, Komatsu M, Tanaka N, Umemura T, Ichijo T, Yoshizawa K, Kiyosawa K, Tanaka E. 2008. Pretreatment prediction of virological response to peginterferon plus ribavirin therapy in chronic hepatitis C patients using viral and host factors. Hepatology 48:1753–1760.

Shiratori Y, Omata M. 2000. Predictors of the efficacy of interferon therapy for patients with chronic hepatitis C before and during therapy: How does this modify the treatment course? J Gastroenterol Hepatol 15:E141–E151.

Suppiah V, Moldovan M, Ahlenstiel G, Berg T, Weltman M, Abate ML, Bassendine M, Spengler U, Dore GJ, Powell E, Riordan S, Sheridan D, Smedile A, Fragomeli V, Muller T, Bahlo M, Stewart GJ, Booth DR, George J. 2009. IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. Nat Genet 41:1100–1104.

Tanaka Y, Nishida N, Sugiyama M, Kurosaki M, Matsuura K, Sakamoto N, Nakagawa M, Korenaga M, Hino K, Hige S, Ito Y, Mita E, Tanaka E, Mochida S, Murawaki Y, Honda M, Sakai A, Hiasa Y, Nishiguchi S, Koike A, Sakaida I, Imamura M, Ito K, Yano K, Masaki N, Sugauchi F, Izumi N, Tokunaga K, Mizokami M. 2009. Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat Genet 41:1105–1109.

Valera VA, Walter BA, Yokoyama N, Koyama Y, Iiai T, Okamoto H, Hatakeyama K. 2007. Prognostic groups in colorectal carcinoma patients based on tumor cell proliferation and classification and regression tree (CART) survival analysis. Ann Surg Oncol 14:34–40.

Yu ML, Dai CY, Huang JF, Chiu CF, Yang YH, Hou NJ, Lee LP, Hsieh MY, Lin ZY, Chen SC, Wang LY, Chang WY, Chuang WL. 2008. Rapid virological response and treatment duration for chronic hepatitis C genotype 1 patients: A randomized trial. Hepatology 47:1884–1893.

Zlobec I, Steele R, Nigam N, Compton CC. 2005. A predictive model of rectal tumor response to preoperative radiotherapy using classification and regression tree methods. Clin Cancer Res 11:5440–5443.

特集・C型肝炎─新時代の治療戦略

C型肝炎治療における
治療効果予測と副作用対策

中川美奈[*]・坂本直哉[**]

Summary

C型慢性肝炎の治療にあたっては，発癌リスクの高い高度線維化症例では，たとえ高齢者であっても積極的な治療介入が必要である。しかし，一方で副作用による中止減量が治療効果の低下につながることが報告されており，高齢患者に対する抗ウイルス治療導入の適応基準が問題となっている。IL28BやITPAを含めた詳細な宿主因子およびウイルス因子解析により治療効果や副作用を事前予測し，抗ウイルス療法導入症例を慎重に見極めることが重要であり，導入症例では治療完遂を目指し，適宜投薬調整を行い，薬物治療を含めた早期の副作用対策を行うことが重要である。

Key Words　C型慢性肝炎／GWAS／IL28B／ITPA

はじめに

　高齢化社会が進むにつれ本邦におけるC型慢性肝炎（CHC）・肝硬変患者の平均年齢は上昇し，高齢患者からの肝発癌が増加しているなかで，治療効果と安全性を的確に評価し治療方針を決定する必要がある。C型肝炎の自然経過をみると，平均8～10年で線維化ステージは1段階上昇し，線維化が進むにつれ発癌率が上昇すること，症例により進展度の早い群と遅い群が存在することが報告されているが[1,2]，発癌リスクの高い高度線維化症例では，たとえ高齢者であっても積極的な治療介入が必要であると考えられる。しかし，

　一方でCHCに対する根治療法であるインターフェロン（IFN）併用治療は副作用による中止減量で十分な投薬量を確保できないことが治療効果の低下につながることが報告されており，高齢患者に対する抗ウイルス治療導入の適応基準が問題となっている。今後，詳細なウイルスおよび宿主因子解析による効果および副作用予測，それに基づく治療法の選択が，さらに重要性を増してくることが予想される。

C型肝炎の自然経過・治療効果とゲノムワイド解析

　2009年ゲノムワイド関連分析法（genome-

＊東京医科歯科大学消化器内科　助教
＊＊北海道大学消化器内科学分野　教授

278

図1　C 型慢性肝炎患者における IL28B SNP
　　　（rs8099917）の頻度
IL28B ゲノタイプの頻度は TT：73.1%，TG：
25.8%，GG：1.0%であり，マイナーアリル（G）
頻度は0.139であった（自験例）。

wide association study：GWAS）により，19
番染色体上の IL28B 遺伝子周辺に治療無効
に強く関連する一連の有意な遺伝子多型
（SNP）が存在することが報告された[3]。治療
効果予測と IL28B の関連を示す同様の報告
は，わが国を含めて3つの独立した研究グ
ループからほぼ同時期に報告され，人種を越
えた遺伝要因であることが証明され[4,5]，さら
に Thomas らにより IL-28B SNP が C 型急
性肝炎の自然治癒率にも関連することが報告
された[6]。

　IL28B 遺伝子座には IFN 治療効果に強く
関連する複数の SNP が存在するが，これら
はすべてが強い連鎖不平衡を伴っておりハプ
ロタイプを形成している。したがって，最も
関連の強い特定の一つの SNP（タグ SNP）を
調べれば残りの SNP を推測することができ
る。このタグ SNP としては，現在のところ
rs12979860[5]，または rs8099917[3,4] の2ヵ所
が de facto standard として使用され，それぞ
れ固有の核酸がメジャーアリルおよびマイ
ナーアリルを代表している。SNP の検出法に
はいくつかの方法があるが，少数の特定の
SNP を検出するにはシーケンス法，Taqman

アッセイなどが一般的に用いられる。ゲノタ
イピングを含む遺伝子検査では生涯変化しな
い個人の重要な遺伝学的情報が扱われるため，
検査実施時に，個人の遺伝学的情報の保護，
検査に用いた生体試料の取り扱い，検査前後
の遺伝カウンセリングなどを被検者に十分に
説明し，インフォームド・コンセントを取っ
た上で行わなければならない。また厚生労働
省の「ヒトゲノム・遺伝子解析研究に関する
倫理指針」に則して，しかるべき施設で倫理
委員会の承認を得た上で施行しなければいけ
ない。

IL28B 多型と PEG-IFN・RBV 治療効果

　2004年12月より本学および関連施設で行っ
たペグインターフェロン（PEG-IFN）/リバ
ビリン（RBV）療法の最終効果判定可能で
あった Genotype 1：323例，Genotype 2：
108例を対象に IL28B SNP rs8099917の解析
を行い，ウイルス，宿主因子と併せて治療効
果との関連を検討した。IL28B ゲノタイプの
頻度は TT：73.1%，TG：25.8%，GG：1.0%

279

図2　C型慢性肝炎患者における IL28B SNP（rs8099917）と PEG-IFN/RBV 治療効果（自験例）
IL28B SNP は治療効果と強く関連しており，マイナーアリルを持つ症例では60％が null response であった。一方，IFN 高感受性のウイルスである Genotype 2症例では IL28B 多型にかかわらず良好な治療効果が得られた。

であり，マイナーアリル（G）頻度は0.139であった（図1）。IL28B SNP は治療効果と強く関連しており，Genotype 1患者のウイルス学的著効（SVR）は非高齢者 TT 群58％，高齢者 TT 群40％に比し，非高齢者 TG＋GG 群24％，高齢者 TG＋GG 群9％と有意に低下し，マイナーアリルを持つ症例では60％が null response であった。一方，IFN 高感受性ウイルスである Genotype 2症例は IL28B 多型にかかわらず良好な治療効果が得られており，高齢者 TG＋GG 群でも比較的良好な SVR が得られた（図2）。

これまでの PEG-IFN/RBV 療法における治療効果の検討では，Genotype 1症例でも ISDR 変異2以上の症例は Genotype 2同様に治療効果が良好であることは複数施設より報告があり，自験例でも Genotype 1かつ ISDR 変異2以上の症例は IFN 高感受性であり，Genotype 2とほぼ同等の SVR が得られることを報告したが[7]，IL28B 多型別に治療中の経時的 HCV 陰性化率を比較すると Genotype 1かつ ISDR 変異2以上の症例や Gen-otype 2など治療高感受性のウイルスでは，IL28B が治療効果に与える影響は弱いことが確認された[8]。一方，ISDR 変異1以下の症例では IL28B マイナーアリル症例で有意に治療効果は低下し，高率に null response となる。STAT-C 治療薬の第一号として認可されたテラプレビル（TPV）を加えた3剤併用療法の治験では IL28B マイナーアリルの症例で前治療 null response の場合，SVR 30％程度と十分な治療効果は得られておらず，ウイルス側抵抗因子であるコア変異[9,10]と宿主側抵抗因子である IL28B 変異とを組み合わせることで，TPV 併用3剤併用療法の効果をより詳細に予測できることも報告されている[11]。これらの知見は臨床上も非常に有意義なデータであるとともに，治療抵抗症例に対する有効な治療法開発に向けて，IL28B やコア変異がいかに治療抵抗機序へ関与しているか解明することが，今後の最重要事項の一つと考えられる。

図3　ITPA 多型と血球減少

Genotype 1型に対する PEG-IFN/RBV48週治療における経時的な血球減少の推移を
ITPA 別に示してみると，貧血に関しては，ITPA マイナーアリルを持つ症例では治療早
期，経過中を通じて貧血は有意に抑制されたが，血小板に関しては逆の傾向を示し，ITPA
マイナーアリルを持つ症例では治療早期で血小板低下が顕著であった（*p＜0.05）。

<div align="right">（文献13より）</div>

▶ ITPA と血球減少

　2010年 GWAS により，CHC 治療における貧血と関連する SNP として，Inosine triphosphatase（ITPA）遺伝子座の2つの SNP（rs11277354，rs7270101）が同定された[12]。ITPA は ITP を IMP に脱リン酸化する酵素であり，マイナーアリルを持つ患者（CA/AA）は ITPA 活性が低下または欠損している。そもそも RBV による溶血性貧血は，赤血球に蓄積した RBV によって IMPDH 活性が抑制されることで赤血球 GTP が減少し，それによりもたらされる ATP レベルの低下が抗酸化ストレス作用を減弱させ，溶血をき

たすと考えられている。ITPA のマイナーアリルを持つ患者は ITPA 活性が低いため赤血球内に ITP が蓄積し GTP 減少を代償するため，ATP レベルの低下が抑えられ溶血も起こりにくくなる。ITPA マイナーアリルを持つ CHC 患者は PEG-IFN/RBV 治療早期の貧血が抑制され，自験例でも治療開始2週，4週の Hb 低下は ITPA マイナーアリル症例で有意に小さいことが確認された（2週：$p=6.6\times10^{-13}$，4週：$p=3.0\times10^{-29}$）[13]。この結果として RBV 減量が必要になる患者の割合や RBV 減量までの期間，RBV 予定投与量達成率との関連も報告されている。

　ITPA SNP は PEG-IFN/RBV 治療中の血小板減少とも関連することが知られ，貧血と

<div align="right">281</div>

図4　ITPA 多型-治療前血小板値と治療効果の関係（自験例，左：Genotype 1，右：Genotype 2）
治療前血小板値が13万/μL 以下では，ITPA マイナーアリルを持つ症例は ITPA メジャーアリルを持つ症例に比し SVR 率は低下した。肝線維化進展のみられる血小板低値例では ITPA マイナーアリルであることが，血小板低下による薬剤減量により治療効果低下につながることが示唆された。

血小板減少は逆の相関であり，マイナーアリルを持つ患者において血小板減少が強くなる[14]。これは貧血の軽度なマイナーアリルでは，溶血性貧血に対する代償機能としての反応性造血亢進が弱くなるためと考えられているが，血小板減少と ITPA SNP の関連は貧血と独立であるとの報告もあり，IFN 誘導性血小板減少と ITPA SNP の間の直接の相互作用も示唆されるなど，今後の解析が待たれる。自験例においても Genotype 1型に対する PEG-IFN/RBV 48週治療における経時的な血球減少の推移を ITPA 別に示してみると，貧血に関しては，ITPA マイナーアリルを持つ症例では治療早期，経過中を通じて貧血は有意に抑制されたが，血小板に関しては逆の傾向を示し，ITPA マイナーアリルを持つ症例では治療早期で血小板低下が顕著であった（図3）[15]。白血球減少に関する同様の解析では白血球減少と ITPA SNP との関連は認められなかった。

　貧血と血小板減少という，投薬量の調節に重要な血球減少が同じ宿主遺伝子で逆の動きをしていることから，実際どちらがより強く

表1　副作用中止（自験例 656例での解析）

	65歳未満	65歳以上
食欲不振・倦怠感	14人	5人
血球減少	8人	0人
皮疹（乾癬含む）	8人	2人
精神症状	8人	4人
IFN 網膜症，眼底出血	4人	4人
間質性肺炎（疑い）	4人	2人
悪性腫瘍（HCC 含む）治療	6人	2人
甲状腺機能低下症	3人	0人
感染症（骨盤腹膜炎）	1人	1人
合併症悪化（DM，胆石症）	0人	1人
心疾患（胸痛，不整脈）	0人	2人
鼠径ヘルニア	0人	1人
難聴，脱毛	3人	0人

投薬調節に影響しているのか，自験例でさらに解析を進めたところ，全体としては ITPA マイナーアリルを持つ症例は貧血になりにくいことから RBV 減量例が有意に低く（p＝0.012），ITPA SNP と IFN 減量との間には有意な関連は認められなかったが[13]，治療前血小板値が13万/μL 以下の Genotype 1症例では，ITPA マイナーアリルを持つ症例は SVR の低下を認め，肝線維化進展のみられ

る血小板低値例では ITPA マイナーアリルであることが，血小板低下による薬剤減量により治療効果低下につながることが示唆された（図4）。

その他の副作用

　従来の PEG-IFN/RBV 併用療法では，上述の血球減少のほかに，さまざまな副作用が添付文書にも記載されているが，自験例で副作用中止の内訳を検討したところ，表1に示すように重篤な副作用はなく，いずれも治療中止により速やかに回復した。65歳以上の高齢者は非高齢者に比較して副作用中止は多い傾向にあったが有意差はなく（65歳未満 vs. 65歳以上＝11.8% vs. 15.4%，p＝0.24），適宜投薬調整を行い，薬物治療を含めた早期の副作用対策を行うことが，治療完遂につながるものと思われた。

　2011年本邦でもプロテアーゼ阻害薬である TPV が承認となり，今後 HCV 治療は direct-acting antiviral（DAA）製剤を中心とした多剤併用療法の時代を迎えると思われる。TPV 併用療法では，従来の2剤治療の副作用に加えて，皮疹，貧血，腎機能障害などが強く出ることが報告されているが，現在治験中の第2世代プロテアーゼ阻害薬は副作用の軽減が期待されており，1日も早い臨床現場への登場が期待される。

おわりに

　CHC 患者の高齢化が進むわが国においては，IL28B や ITPA を含めた詳細な宿主因子およびウイルス因子解析により治療効果や副作用を事前予測し，抗ウイルス療法導入症例を慎重に見極めることが治療の質の向上に重要である。今後，新規薬剤の登場とともに高齢者でも負担の少ない治療法の開発が期待される。PEG-IFN 併用療法では根治の見込める患者を高い的中率で選別し，治療高感受性で高い治癒率が期待される場合は治療導入を強く勧め，また治療抵抗性と判定された患者は STAT-C 併用療法，あるいは PEG-IFN-λ療法に振り替えるなど，治療のオーダーメイド化の展開が期待される。

文　献

1）Poynard T, Bedossa P, Opolon P：Natural history of liver fibrosis progression in patients with chronic hepatitis C. Lancet 349：825-832（1997）
2）Shiratori Y, Imazeki F, Moriyama M et al：Histologic improvement of fibrosis in patients with hepatitis C who have sustained response to interferon therapy. Annals of Internal Medicine 132：517-524（2000）
3）Tanaka Y, Nishida N, Sugiyama M et al：Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat Genet 41：1105-1109（2009）
4）Suppiah V, Moldovan M, Ahlenstiel G et al：IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. Nat Genet 41：1100-1104（2009）
5）Ge D, Fellay J, Thompson AJ et al：Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 461：399-401（2009）
6）Thomas DL, Thio CL, Martin MP et al：Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature 461：798-U752（2009）
7）Nakagawa M, Sakamoto N, Ueyama M et al：Mutations in the interferon sensitivity deter-

mining region and virological response to combination therapy with pegylated-interferon alpha 2b plus ribavirin in patients with chronic hepatitis C-1b infection. Journal of Gastroenterology **45**：656-665（2010）

8 ）Sakamoto N, Nakagawa M, Tanaka Y *et al*： Association of IL28B Variants With Response to Pegylated-Interferon Alpha Plus Ribavirin Combination Therapy Reveals Intersubgenotypic Differences Between Genotypes 2a and 2b. Journal of Medical Virology **83**：871-878（2011）

9 ）Akuta N, Suzuki F, Sezaki H *et al*：Association of amino acid substitution pattern in core protein of hepatitis C virus genotype 1b high viral load and non-virological response to interferon-ribavirin combination therapy. Intervirology **48**：372-380（2005）

10）Akuta N, Suzuki F, Sezaki H *et al*：Predictive factors of virological non-response to interferon-ribavirin combination therapy for patients infected with hepatitis C virus of genotype 1b and high viral load. Journal of Medical Virology **78**：83-90（2006）

11）Akuta N, Suzuki F, Hirakawa M *et al*：Amino Acid Substitution in Hepatitis C Virus Core

Region and Genetic Variation Near the Interleukin 28B Gene Predict Viral Response to Telaprevir with Peginterferon and Ribavirin. Hepatology **52**：421-429（2010）

12）Fellay J, Thompson AJ, Ge DL *et al*：ITPA gene variants protect against anaemia in patients treated for chronic hepatitis C. Nature **464**：405-408（2010）

13）Sakamoto N, Tanaka Y, Nakagawa M *et al*： ITPA gene variant protects against anemia induced by pegylated interferon-alpha and ribavirin therapy for Japanese patients with chronic hepatitis C. Hepatology Research **40**： 1063-1071（2010）

14）Tanaka Y, Kurosaki M, Nishida N *et al*： Genome-wide association study identified ITPA/DDRGK1 variants reflecting thrombocytopenia in pegylated interferon and ribavirin therapy for chronic hepatitis C. Human Molecular Genetics **20**：3507-3516（2011）

15）Nakagawa M, Sakamoto N, Watanabe M *et al*： Association of ITPA gene variation and serum ribavirinconcentration with a decline in blood cell concentrations during pegylated interferon-alpha plus ribavirin therapy for chronic hepatitis C. Hepatol Int（2012）[Epub]

284

Gastrointestinal Research

HCV 治療抵抗性関連遺伝子の同定と治療展開

中川美奈* 坂本直哉**

Summary

インターロイキン（IL）28B の遺伝子多型は，2009 年にはじめて C 型肝炎の治療効果に関連する遺伝子として報告された．IL28B 遺伝子座の代表的な一塩基置換（SNP）である rs8099917 の minor allele（TG, GG）をもつ患者群は，もたない（TT）患者群にくらべ強い有意差をもってペグインターフェロン・リバビリン（PEG-IFN・RBV）療法が無効であることが報告されたが，テラプレビル（TPV）を加えた 3 剤併用療法においても治療抵抗性の予測因子として重要であることが報告されている．C 型慢性肝炎の治療にあたっては，IL28B を含めた詳細な宿主およびウイルス因子解析による治療前効果予測により，根治の見込める患者を高い的中率で選別し，治療導入を強く勧め，また治療抵抗性と判定された患者は STAT-C 併用療法，あるいは PEG-IFN-λ 療法に振り替えるなど，治療のオーダーメイド化の展開が期待される．

Key words

C 型慢性肝炎 ゲノムワイド関連解析（GWAS） インターロイキン（IL）28B 治療抵抗性 インターフェロン（IFN）-λ

はじめに

慢性活動性肝炎患者の肝病態進展の阻止にウイルス排除は不可欠であるが，わが国における C 型慢性肝炎の抗ウイルス療法は，1992 年に認可されたインターフェロン（IFN）がその中心的役割を果たしてきた．持続型 IFN 製剤であるペグインターフェロン（PEG-IFN）は，その簡便性および有効性，さらにリバビリン（RBV）との併用による再燃抑制効果が認められ，PEG-IFN・RBV 併用療法が日本および世界の標準治療となったが，

難治例であるゲノタイプ 1 型高ウイルス量症例の sustained virological response（SVR）率は 50%前後であり[1,2]，長期にわたる治療期間や副作用の問題，また副作用などによる薬剤の中止減量が治療効果低下につながることが課題となっていた．また IFN に対する反応性には人種間の差があり，遺伝的な治療感受性決定因子の存在も以前から示唆されていた[3]．一方，2000 年にヒトゲノムの配列が決定されて以来，近年の遺伝子情報処理技術の飛躍的な進歩による網羅的なゲノムワイド関連解析（genome-wide association study：GWAS）

＊NAKAGAWA Mina/東京医科歯科大学消化器内科
＊＊SAKAMOTO Naoya/北海道大学大学院医学研究科内科学講座消化器内科学分野